Median Technologies to Showcase Lung Cancer Screening AI Performance at CHEST 2026

  • Median Technologies' subsidiary eyonis Inc. will present study results at CHEST 2026 (Oct 18-21, 2026) supporting its lung cancer screening AI software.
  • The study showed eyonis® LCS achieved 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value in a cohort of 2,163 patients.
  • eyonis® LCS received FDA 510(k) clearance in February 2026 and is commercially available in the U.S.
  • The presentation will be made by Benoit Huet, PhD, Senior VP of AI Engineering and Research at Median Technologies.

Median Technologies is positioning itself as a leader in AI-powered early cancer detection, with eyonis® LCS representing a strategic pivot toward clinical applications beyond its traditional focus on oncology drug development. The CHEST 2026 presentation comes at a critical time as lung cancer screening programs expand in the U.S., creating a growing market for AI-enabled diagnostic tools. The company's ability to demonstrate superior clinical performance metrics will be key to differentiating its offering in a competitive landscape.

Adoption Dynamics
How the clinical performance data will accelerate eyonis® LCS adoption among pulmonologists and screening centers.
Competitive Positioning
Whether Median can maintain its lead as the only FDA-cleared AI/ML-based SaMD combining detection and diagnosis in lung cancer screening.
Regulatory Expansion
The pace at which Median can secure additional regulatory clearances beyond the U.S. for eyonis® LCS.